Morepen Laboratories Limited (MOREPENLAB) submits its first U.S. ANDA for Sitagliptin Tablets, enhancing its CDMO capabilities.
Morepen Laboratories Limited (NSE: MOREPENLAB) reports highest-ever quarterly revenue and earnings for Q1 FY27, with EBITDA up 207% and PAT up 394%.
Morepen Laboratories Limited (MOREPENLAB) has initiated commercial supplies under its ₹825 crore CDMO mandate, completing the first ₹50 crore dispatch in Q1F.
Morepen Laboratories Limited (MOREPENLAB) reports a 69% YoY net profit rise in Q4 FY26, with gross revenue up 22% to Rs. 472 Cr.